Placenta Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia and Normotensive Pregnant Nigerian Women

Gbadegesin, Abidoye; Agbara, J. O.; Rabiu, Kabiru Afolarin; Sobande, Adekunle A.; Azeez, Madinah A.

doi:10.4236/ojog.2021.116070

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of the present study are consistent with the results of Fillion et al, (2020) [36] and Fillion et al, (2021) [37] that documented decreased serum level of PIGF in preclampsia which may be due to the higher maternal blood levels of soluble fms-like tyrosine kinase-1 (sFlt-1), an inhibitor of PIGF, and subsequent lower levels of PlGF which appear before the clinical onset and is used for the anticipation of PE. Additionally, our results with a significantly lower maternal blood PIGF level in high-risk PE, are consistent with the findings of Gbadegesin, et al, (2021) [38] Additionally, they showed that little is known about the mechanisms underlying the altered maternal plasma PIGF concentrations in women with PE. While inadequate remodeling of spiral arteries and neoangiogenesis, which are crucial for health and growth in a typical conception, may arise from reduced oxygen tension in the placenta, in-vitro studies indicate that these factors' altered amounts may occur as a result.…”

Section: Discussionsupporting

confidence: 92%

First trimester screening and prediction of preeclampsia by Application of Fetal Medicine Foundation Algorithm at Tanta University

Ismail¹,

Hamamy²,

Abdallah³

et al. 2023

Int. J. Clin. Obstet. Gynaecol.

View full text Add to dashboard Cite

Background: Preeclampsia (PE) is a complex illness linked to conception that affects a variety of bodily functions and is usually connected with perinatal morbidity and deaths. Early PE anticipation will reduce this linked morbidity and death by allowing for routine maternal and foetal monitoring and the use of preventative measures. Aim of the work: the goal of this study is to investigate whether the measurement of maternal serum placental growth factor (PlGF) combined with uterine artery Doppler ultrasound, are useful in early predicting PE and to examine the diagnostic accuracy of the Fetal Medicine Foundation (FMF) Algorithm for the early screening and anticipation of the high-risk PE at 11-13 weeks conception in a group of pregnant women. Patients and Methods: one hundred and twenty primigravida women with living, singleton fetus at 11-13 weeks conception without risk factors other than being primigravida attending antenatal care clinic at the Department of Obstetrics and Gynecology at Tanta University Hospitals. All cases were subjected to ; A signed informed written consent, proper history taking, full clinical examination, estimation of body mass index (BMI), blood pressures and determination of mean arterial blood pressure (MAP), ultrasound, Uterine artery doppler ultrasound examination with the determination of the mean Pulsatility index (PI) of the uterine arteries. Maternal serum levels of PlGF were also measured by specific immunoassay (ELISA). The measured values of MAP, mean uterine artery pulsatility index (PI) and PlGF were converted into multiples of the median (MoM). Then the FMF model was used for the determination of patient-specific risk of PE at 11-13 weeks conception in each case. Results:The main results of the present study revealed that; Only 11 of 120 normal pregnant women were categorized as a high PE risk with a percentage of 9.2% and the rest 109 cases were low PE risk with a percentage of 90.8% by application of FMF algorithm. There was a significant difference between the high and low risks regarding the mean uterian UtA-Pi and PIGF levels at 11-13 weeks. Receiver operating characteristic curve (ROC) demonstrate to what extent it can be depended on PlGF, mean UtA-PI and MAP as a predictor for PE denoting the significant diagnostic performance for PIGF and mean uterine artery pulsatility index (PI). The optimal cutoff value of PlGF value using the ROC curve was ≤40 leading to a sensitivity of 90.91%, a specificity of 96.33%, a PPV of 71.4, a NPV of 99.1% and an accuracy of 95.83%. While the optimal cutoff measure of mean uterine artery PI value using the ROC curve was >1.91 leading to a sensitivity of 90.91%, a specificity of 96.33%, PPV of 71.4, NPV of 99.1% and an accuracy of 95.83%. Conclusion:On the basis of these results, it could be concluded that the combined measurement of maternal serum PlGF concentrations and mean PI of the uterine arteries at 11-13 weeks of conception may help to predict the high-risk PE in primigravida when other parameters of PE anticipation are norm...

show abstract

Section: Discussionsupporting

confidence: 92%

First trimester screening and prediction of preeclampsia by Application of Fetal Medicine Foundation Algorithm at Tanta University

Ismail¹,

Hamamy²,

Abdallah³

et al. 2023

Int. J. Clin. Obstet. Gynaecol.

View full text Add to dashboard Cite

show abstract

“…During the second trimester, sFlt1 and PlGF have shown significant sensitivity in predicting the development of PE (Figure 1) and a high sFlt1:PlGF ratio may also indicate this condition. However, additional clinical research, particularly randomized trials, will be required to determine their utility [34].…”

Section: Soluble Fms Like Tyrosine Kinase-1 (Sflt-1)mentioning

confidence: 99%

The role of biomarkers in early prediction and molecular mechanisms of preeclampsia

Kalarani¹,

Veerabathiran²,

Mohammed³

2022

Eur J Trans Clin Med

View full text Add to dashboard Cite

Preeclampsia (PE) is defined as new onset hypertension after 20 weeks of gestation with evidence of maternal organ or uteroplacental dysfunction or proteinuria. PE is a leading cause of maternal death, with about 55000 deaths worldwide each year. Toxic substances that damage the maternal vascular endothelium induce PE, resulting in liver and kidney malfunction. It is crucial for obstetricians to identify as early as possible the patients who are at risk for PE. Polycystic ovarian disease, sleeping disorders, urinary infections, periodontal disease, smoking, lifestyle and familial history of PE are the major risk factors involved in this disease. VEGF, sFlt1, sENG, PAPP-A, inhibin A and activin A proteins, fetal hemoglobin, heat shock protein and placental protein have been helpful in predicting or diagnosing PE and in understanding its pathogenesis. In addition, a better understanding of PE pathogenesis would aid in identifying the most effective treatments that do not impair the fetus' prognosis. The aim of our study is a review of the pathophysiology and biomarkers, such as pro-and anti-angiogenic substances, that may be useful in the detection of PE in the future.

show abstract

Association of angiogenic factors (placental growth factor and soluble FMS-like tyrosine kinase-1) in preeclamptic women of African ancestry comorbid with HIV infection

Mlambo,

Sebitloane,

Naicker

2024

Arch Gynecol Obstet

View full text Add to dashboard Cite

Background Preeclampsia is a significant cause of maternal and fetal morbidity and mortality, particularly in low- and middle-income countries like South Africa. Aim The aim of our study was to investigate the association between placental growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1) in South African preeclamptic women of African ancestry, comorbid with HIV infection. Methods The study population consisted of women attending a regional hospital in Durban, South Africa, stratified by pregnancy type (normotensive pregnant and preeclampsia) and HIV status. Preeclampsia was defined as new-onset hypertension and proteinuria. DNA was obtained from whole blood. The SNPs of interest were rs722503 in sFlt-1 and rs4903273 in PlGF. Results Our findings suggest that single nucleotide polymorphisms of rs722503 analysis show no significant associations between the genotypic frequencies of rs722503 variants and preeclampsia risk in either HIV-negative or HIV-positive groups of women of African ancestry. Similarly, the rs493273 polymorphism showed no significant association with preeclampsia risk in either HIV-negative or HIV-positive pregnant women. Additionally, comparisons of dominant, recessive, and over-dominant allele models did not reveal significant associations. These findings suggest that these genetic variants may not significantly contribute to preeclampsia development in this African ancestry population. However, significant differences were observed in the rs4903273 genotype frequencies between normotensive and preeclamptic women, regardless of HIV status, over dominant alleles AA + GG vs AG showed a significant difference [OR = 2.706; 95% Cl (1.199–5.979); adjusted p = 0.0234*], also in normotensive compared to EOPE (OR = 2.804; 95% Cl (1.151–6.89) p = 0.0326* and LOPE (OR = 2.601; 95% Cl (1.0310–6.539) p = 0.0492*), suggesting that they may be the potential role of this variant in preeclampsia susceptibility. Conclusion The findings suggest that the rs722503 and rs493273 polymorphisms do not significantly contribute to preeclampsia susceptibility in HIV-negative or HIV-positive pregnant women. However, the rs4903273 genotype frequencies showed notable differences between normotensive and preeclamptic women, indicating a potential association with preeclampsia development in the African ancestry population irrespective of HIV status.

show abstract

Placenta Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia and Normotensive Pregnant Nigerian Women

Cited by 3 publications

References 28 publications

First trimester screening and prediction of preeclampsia by Application of Fetal Medicine Foundation Algorithm at Tanta University

First trimester screening and prediction of preeclampsia by Application of Fetal Medicine Foundation Algorithm at Tanta University

The role of biomarkers in early prediction and molecular mechanisms of preeclampsia

Association of angiogenic factors (placental growth factor and soluble FMS-like tyrosine kinase-1) in preeclamptic women of African ancestry comorbid with HIV infection

Contact Info

Product

Resources

About